Dual GIP / GLP-1 receptor agonist
Tirzepatide
Also known as Mounjaro, Zepbound.
Stage Approved
Indications Type 2 Diabetes, Obesity
Last updated:Jul 15, 2026Source:ClinicalTrials.gov + sponsor pipeline pagesVerified:Manually reviewedData provider:PeptidePlanet Research
Mechanism
Co-agonism of GIP and GLP-1 receptors driving weight and glycemic effects.
Educational summary. Not medical advice. See sponsor materials and peer-reviewed literature for full pharmacology.
Companies developing it
1Related trials
2Current research
Data unavailableCurated peer-reviewed research links launch once our editorial pipeline is verified.
Safety summary
Data unavailableSafety summaries require a verified regulatory data source and clinical review. Consult the FDA label and sponsor prescribing information for approved products.